Business Wire

THERAMEX

21.9.2021 13:47:12 CEST | Business Wire | Press release

Share
Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women*

PRESCRIBING INFORMATION IS AVAILABLE AT THE END OF THIS RELEASE

FOR MEDICAL BUSINESS / HEALTHCARE INDUSTRY TRADE MEDIA ONLY

Theramex has today launched Bijuva® / Bijuve® (1mg estradiol / 100mg progesterone) across Europe and the UK. Bijuva® , (known as Bijuve® in the UK), is the first, and only, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in post-menopausal women with intact uterus and at least 12 months since last menses, which combines estradiol and progesterone in a single daily oral capsule.1,2 Unlike synthetic hormone products, the estradiol and progesterone found in Bijuva® / Bijuve® are chemically and biologically identical to the hormones naturally circulating in the woman’s body.3

Real-world evidence, recognised by NICE and the British Menopause Society, suggests that use of body‑identical hormones is associated with lower risks compared to synthetic versions. 4,5 In particular, the evidence base demonstrates that body-identical hormones have not been shown to increase the risk of venous thromboembolism and are safer forms of HRT with respect to the risk for breast cancer, heart disease, heart attack, and stroke.6-8

The idea of using body identical hormones to replace estrogens and to protect the endometrium with progesterone appeals to many women9 . These hormones that many women prefer are now available in a combined single capsule that has been shown to be effective and well-tolerated.1,9

Dr Paula Briggs, incoming Chair of the British Menopause Society, said, “We know women can be concerned about taking hormones and the impact they may have on their health beyond treating menopause symptoms. The availability of a body-identical progesterone which is well tolerated and has a lower risk profile than oral synthetic progestogens, combined with estradiol in a single capsule, is great news for women. As a healthcare community we should encourage our patients to reconsider the benefits of newer therapeutic options, allowing them to make informed choices.”

Theramex CEO, Robert Stewart, commented, “For many years menopausal women and their healthcare providers have been seeking an EMA approved body-identical combination therapy. The approval of Bijuva® / Bijuve® during Menopause Awareness month represents an important new opportunity for menopausal women suffering from moderate to severe vasomotor symptoms.”

ENDS

Notes to Editor

About Bijuva® / Bijuve®

Bijuva® / Bijuve® is a fixed dose, oral, continuous combined hormonal replacement therapy (HRT) capsule containing 1mg estradiol and 100mg micronised progesterone.1 Known as Bijuve® in the UK, it is the first approved oral continuous combined body-identical estradiol–progesterone formulation in a single capsule.2 It is indicated for continuous combined HRT for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses.1 In a robust, long-term, phase III clinical trial, Bijuva® / Bijuve® demonstrated clinically relevant and statistically significant improvement in the reduction of frequency and severity of moderate-to-severe vasomotor symptoms (VMS) such as hot flushes and night sweats as early as week 3 vs placebo.9 It also demonstrated significant improvement in sleep without causing drowsiness, which delivered a significant improvement in quality of life for women taking part in the study.9 Importantly Bijuva® / Bijuve® safety was studied over 12 months of treatment, and demonstrated endometrial protection, as well as no significant changes in lipid, coagulation or glucose parameters as compared to placebo.9

The most common adverse reactions (≥3 percent) were breast tenderness, headache, vaginal bleeding, vaginal discharge and vaginal hemorrhage.9 Theramex has a license and supply agreement with TherapeuticsMD (Nasdaq: TXMD) to commercialize BIJUVA outside the United States, Canada and Israel.10

The burden of menopause

During menopause, patients may experience undesirable symptoms including vasomotor symptoms (VMS) such as hot flushes and night sweats. 11-15 In addition, women may also experience sleep deprivation, headaches, inability to concentrate, loss of memory, mood swings, vaginal dryness, loss of libido and stiffness of joints and muscles, all of which can deteriorate their quality of life. 11-15 It is estimated that vasomotor symptoms are experienced by around 75% of menopausal women and for around a third of these women, symptoms are severe.5 Up to three-quarters of post-menopausal women experience sleep disorders, which negatively impact health-related quality of life (HRQoL) and work productivity.16,17 Menopausal symptoms can typically last around 4 years, and in around 10% of women can last up to 12 years post-menopause.4 Direct and indirect costs associated with caring for women with VMS are significantly higher than for women without VMS.16,18

About Theramex

Theramex is a leading, global speciality pharmaceutical company dedicated to women and their health. With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, we support women at every stage of their lives. Our commitment is to listen and understand our patients, serve their needs, and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them, by providing innovative and effective solutions that care for and support women as they advance through each stage of their lives.

References

* With intact uterus and at least 12 months since last menses

1 Theramex 2021, Summary of Product Characteristics

2 FDA Summary Review. 2018. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210132Orig1s000SumR.pdf . Accessed September 2021.

3 Kuhl H. 2005;8(Suppl 1):3-63.

4 National Institute for Health and Care Excellence. Available at https://www.nice.org.uk/guidance/ng23/ . Accessed September 2021.

5 British Menopause Society. Available at https://thebms.org.uk/publications/consensus- statements/hormone-replacement-therapy/ . Accessed September 2021.

6 Holtorf K. Postgrad Med. 2009;121(1):73–85.

7 Mirkin S. Climateric. 2018;21(4):346-354.

8 Fournier A, Berrine F, Clavel-Chapelon F. Breast Cancer Res Treat. 2008;107:103-111.

9 Archer DF, Bernick BA, Mirkin S. Expert Rev Clin Pharmacol. 2019;12(8):729–39.

10 Theramex. (7th June 2019). https://www.sec.gov/Archives/edgar/data/25743/000138713119004260/ex99-1.htm

11 Davis SR et al. Nat Rev Dis Primers. 2015;1: 15054. Menopause. Nat Rev 2015;1:1-19

12 Greendale GA et al. JAMA. 2020;323(15):1495-6.

13 Joffe Het al. Clin Endocrinol Metab. 2016; 101(10): 3847-55.

14 Zervas IM et al. Menopause. 2009;16(4): 837-42.

15 Jehan S et al. J Sleep Disord Ther. 2015;4(5):1-18.

16 DiBonaventura MD et al. Int J Womens Health. 2013;5:261–9.

17 Baker FC et al. Sleep Med Clin. 2018;13(3):443–56.

18 Sarrel P et al. Menopause. 2015;22(3):260–6.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac

ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release

Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo

North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release

Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene

Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press release

Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally req

From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press release

The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye